






*Participants who achieved weight loss threshold (≥5 kg or 5% if baseline body weight was <100 kg) during the 10-week open-label period
The mean percentage change in the most hunger score was −27.1% (n=7; 90% CI −40.6 to −15.0; P=0.0005), which is clinically meaningful2
50% of participants achieved a predefined clinically meaningful ≥25% improvement in hunger score from baseline at 1 year2
When IMCIVREE was withdrawn in participants who had lost weight during the 10-week open-label period, the mean hunger scores increased over the 4 weeks of placebo treatment2
The mean percentage change in the most hunger score was −43·7% (n=7; −54.8 to −29.1; P<0.0001)2
73% of participants achieved a predefined clinically meaningful ≥25% improvement in hunger score from baseline at 1 year2
When IMCIVREE was withdrawn in participants who had lost weight during the 10-week open-label period, the mean hunger scores increased over the 4 weeks of placebo treatment2

Hyperpigmentation disorders
56%
Injection site reactions
45%
Nausea
31%
Headache
20%
IMCIVREE is an MC4R agonist with some activity at the melanocortin 1 (MC1) receptors. Activation of MC1 leads to accumulation of melanin and increased skin pigmentation. This effect is reversible upon discontinuation of treatment1
Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new skin pigmentary lesions1
Changes in skin pigmentation or hair colour primarily occurred within the first month of treatment1
Injection site reactions, nausea, and vomiting most often occurred within the first month after starting treatment, and then decreased over time1

No serious treatment-related AEs were reported2
There was no treatment-related worsening of depression2


The prescribing physician should periodically assess response to IMCIVREE therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated.
All adverse events should be reported. For medical information, to report an adverse event or product complaint please contact eu_medinfo@rhythmtx.com